

## Lars Rebien Sørensen nominated to join the Boards of Directors of the Novo Nordisk Foundation and Novo A/S

Press release, 1 September 2016

Following the announcement that Lars Rebien Sørensen will relinquish his role as CEO of Novo Nordisk A/S at the end of 2016, the Novo Nordisk Foundation and Novo A/S will nominate Lars Rebien Sørensen as a candidate to the two Boards of Directors in March 2017.

“We have great respect for the results achieved by Lars Rebien Sørensen during his sixteen years at the helm of Novo Nordisk A/S,” says Sten Scheibye, Chairman, Novo Nordisk Foundation and Novo A/S. “With the competences and experience that Lars Rebien Sørensen has, we found it obvious to ask him to consider standing for election to the Boards of Directors of the Novo Nordisk Foundation and Novo A/S. I am very pleased to confirm that Lars Rebien Sørensen has agreed to take on this dual responsibility.”

### **Further information**

Sten Scheibye, Chairman, Novo Nordisk Foundation and Novo A/S.  
Contact Christian Mostrup Scheel, Press Officer, [cims@novo.dk](mailto:cims@novo.dk), +45 3067 4805

### **About the Novo Nordisk Foundation**

The Novo Nordisk Foundation is a Danish foundation with corporate interests. The Foundation has two objectives: 1) to provide a stable basis for the commercial and research activities of the companies in the Novo Group; and 2) to support scientific, humanitarian and social purposes.

The vision of the Foundation is to contribute significantly to research and development that improves the health and welfare of people.

Since 2010, the Foundation has donated more than DKK 9 billion, primarily for research at public institutions and hospitals in Denmark and the other Nordic countries. Read more at [www.novonordiskfoundation.com](http://www.novonordiskfoundation.com).

### **About Novo A/S**

Novo A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.

The company is the holding company in the Novo Group and responsible for managing the Foundation's assets. Besides being the major shareholder in the Novo Group companies, Novo A/S provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within the life sciences and manages a broad portfolio of financial assets. Read more at [www.novo.dk](http://www.novo.dk).